## Madlen Marx

## List of Publications by Year

 in descending orderSource: https:/|exaly.com/author-pdf/8157851/publications.pdf
Version: 2024-02-01


| 1 | Reduction of CD11b <sup>+<\|sup> myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD <sub>2</sub> antibody ch14.18/CHO. Oncolmmunology, 2020, 9, 1836768. | 4.6 | 6 |
| :---: | :---: | :---: | :---: |
| 2 | GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. Journal of Neuro-Oncology, 2020, 147, 577-585. | 2.9 | 18 |
| 3 | Low CD4â̊/CD25â8/CD127â» regulatory T cell- and high INF-î3 levels are associated with improved survival neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. Oncolmmunology, 2019, 8, 1661194. | 4.6 | 14 |
| 4 | Co-expression of IL-15 enhances anti-neuroblastoma effectivity of a tyrosine hydroxylase-directed DNA vaccination in mice. PLoS ONE, 2018, 13, e0207320. | 2.5 | 5 |
| 5 | Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers, 2018, 10, 387. | 3.7 | 13 |
| 6 | PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD<sub>2</sub> antibody ch14.18/CHO. Oncolmmunology, 2017, 6, e1343775. | 4.6 | 53 |
| 7 | Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. Oncolmmunology, 2016, 5, e1235108. | 4.6 | 39 |
| 8 | Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2. MAbs, 2016, 8, 604-616. | 5.2 | 43 |
| 9 | Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD2 Antibody. PLoS ONE, 2014, 9, el07692. | 2.5 | 25 |

